Skip to main content
Top
Published in: Current Atherosclerosis Reports 2/2010

01-03-2010

The Role of Smoking Cessation in the Prevention of Coronary Artery Disease

Authors: Andrew L. Pipe, Sophia Papadakis, Robert D. Reid

Published in: Current Atherosclerosis Reports | Issue 2/2010

Login to get access

Abstract

Smoking (tobacco addiction) is the most significant of the modifiable cardiovascular risk factors. Mistakenly described as a “habit” or “behavioral choice,” the onset of tobacco addiction quickly follows the acquisition of an ability to inhale cigarette smoke and is reflected in a transformation of neurophysiologic function and nicotine-receptor density. Thereafter, comfort and a degree of neurophysiologic “equanimity” require the regular administration of nicotine. Smokers inhale thousands of other chemicals, many of which play critical roles in the initiation and accentuation of atherosclerosis by influencing vasomotor activity, vascular dysfunction, oxidation of lipids, atheroma development, and thrombosis. Smoking cessation is a priority in the management of any patient with cardiovascular disease. The benefits of cessation accrue rapidly in such patients and have a pronounced effect on the likelihood of disease progression, hospital readmission, and mortality. All physicians must be familiar with the principles of cessation practice and be able to initiate smoking cessation attempts.
Literature
1.
go back to reference Orleans CT: Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains in our lifetime. Am J Prev Med 2007, 33:S340–S348.CrossRefPubMed Orleans CT: Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains in our lifetime. Am J Prev Med 2007, 33:S340–S348.CrossRefPubMed
2.
go back to reference Erhardt L: Cigarette smoking: an untreated risk factor for cardiovascular disease. Atherosclerosis 2009, 205:23–32.CrossRefPubMed Erhardt L: Cigarette smoking: an untreated risk factor for cardiovascular disease. Atherosclerosis 2009, 205:23–32.CrossRefPubMed
3.
go back to reference Peto R, Lopez AD, Boreham J, et al.: Mortality from smoking in developed countries 1950–2000: indirect estimation from national vital statistics. Oxford: Oxford University Press; 1994. Peto R, Lopez AD, Boreham J, et al.: Mortality from smoking in developed countries 1950–2000: indirect estimation from national vital statistics. Oxford: Oxford University Press; 1994.
4.
go back to reference The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease and Health Promotion, Office on Smoking and Health; 2004. The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease and Health Promotion, Office on Smoking and Health; 2004.
5.
go back to reference Burns DM: Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis 2003, 46:11–29.CrossRefPubMed Burns DM: Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis 2003, 46:11–29.CrossRefPubMed
6.
go back to reference Critchley JA, Capewell S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86–97.CrossRefPubMed Critchley JA, Capewell S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86–97.CrossRefPubMed
7.
go back to reference Fiore MC, Jaen CR, Baker TB, et al.: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human Services. Public Health Service; 2008. Fiore MC, Jaen CR, Baker TB, et al.: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human Services. Public Health Service; 2008.
8.
go back to reference Ezzati M, Lopez AD: Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 2004, 112:388–395.CrossRef Ezzati M, Lopez AD: Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 2004, 112:388–395.CrossRef
9.
go back to reference Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952.CrossRefPubMed Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952.CrossRefPubMed
10.
go back to reference Peto R, Lopez AD: The future worldwide health effects of current smoking patterns. In Critical Issues in Global Health. Edited by Koop CE, Pearson CE, Schwarz MR. San Francisco, CA: Jossey-Bass; 2001. Peto R, Lopez AD: The future worldwide health effects of current smoking patterns. In Critical Issues in Global Health. Edited by Koop CE, Pearson CE, Schwarz MR. San Francisco, CA: Jossey-Bass; 2001.
11.
go back to reference Law MR, Wald NJ: Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 2003, 46:31–38.CrossRefPubMed Law MR, Wald NJ: Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 2003, 46:31–38.CrossRefPubMed
12.
go back to reference Matturi L, Levezzi AM, Ottaviani G, Rossi L: Intimal preatherosclerotic thickening of the coronary arteries in human fetuses of smoker mothers. J Thromb Haemost 2003, 1:2234–2238.CrossRef Matturi L, Levezzi AM, Ottaviani G, Rossi L: Intimal preatherosclerotic thickening of the coronary arteries in human fetuses of smoker mothers. J Thromb Haemost 2003, 1:2234–2238.CrossRef
13.
go back to reference Zieske AW, McMahan CA, McGill HC Jr, et al.: Smoking is associated with advanced coronary atherosclerosis in youth. Atherosclerosis 2005, 180:87–92.CrossRefPubMed Zieske AW, McMahan CA, McGill HC Jr, et al.: Smoking is associated with advanced coronary atherosclerosis in youth. Atherosclerosis 2005, 180:87–92.CrossRefPubMed
14.
go back to reference Ambrose J, Barua R: The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731–1737.CrossRefPubMed Ambrose J, Barua R: The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731–1737.CrossRefPubMed
15.
go back to reference Suwaidi JA, Hamasaki S, Higano ST: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948–954.PubMed Suwaidi JA, Hamasaki S, Higano ST: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948–954.PubMed
16.
go back to reference Raij L, DeMaster EG, Jaimes EA: Cigarette smoke induced endothelium dysfunction; role of superoxide anion. J Hypertens 2001, 19:891–897.CrossRefPubMed Raij L, DeMaster EG, Jaimes EA: Cigarette smoke induced endothelium dysfunction; role of superoxide anion. J Hypertens 2001, 19:891–897.CrossRefPubMed
17.
go back to reference Pitillo R: Cigarette smoking, endothelial injury and atherosclerosis. J Smoking Related Dis 1993, 4:17–25. Pitillo R: Cigarette smoking, endothelial injury and atherosclerosis. J Smoking Related Dis 1993, 4:17–25.
18.
go back to reference Hamasaki H, Sato J, Matsuda H: Effect of nicotine on the intimal hyperplasia after removal of rabbit carotid artery. Gen Pharmacol 1997, 51:653–659. Hamasaki H, Sato J, Matsuda H: Effect of nicotine on the intimal hyperplasia after removal of rabbit carotid artery. Gen Pharmacol 1997, 51:653–659.
19.
go back to reference Chehne F, Oguogho A, Lupattelli G, et al.: Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis. Prostagland Leukotr Essent Fatty Acid 2002, 67:333–339.CrossRef Chehne F, Oguogho A, Lupattelli G, et al.: Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis. Prostagland Leukotr Essent Fatty Acid 2002, 67:333–339.CrossRef
20.
go back to reference Burke AP, Farb A, Malcolm GT, et al.: Coronary risk factors and plaque morphology n men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276–1282.CrossRefPubMed Burke AP, Farb A, Malcolm GT, et al.: Coronary risk factors and plaque morphology n men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276–1282.CrossRefPubMed
21.
go back to reference Burke AP, Farb A, Malcolm GT, et al.: Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998, 97:2110–2116.PubMed Burke AP, Farb A, Malcolm GT, et al.: Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998, 97:2110–2116.PubMed
22.
go back to reference Fusegawa Y, Goto S, Handa S, et al.: Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 1999, 93:271–278.CrossRefPubMed Fusegawa Y, Goto S, Handa S, et al.: Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 1999, 93:271–278.CrossRefPubMed
23.
go back to reference Powell JT: Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998, 3:21–28.PubMed Powell JT: Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998, 3:21–28.PubMed
24.
go back to reference Newby DE, et al.: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. A mechanism for arterial thrombosis and myocardial infarction. Circulation 1999, 99:1411–1415.PubMed Newby DE, et al.: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. A mechanism for arterial thrombosis and myocardial infarction. Circulation 1999, 99:1411–1415.PubMed
25.
go back to reference Cotti C, Szoli M, Clementi F: Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006, 27:482–491.CrossRef Cotti C, Szoli M, Clementi F: Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006, 27:482–491.CrossRef
26.
go back to reference •• Benowitz N: Pharmacology of nicotine addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009, 49:57–71. This is a succinct description of the mechanisms underlying tobacco addiction and the principles surrounding its treatment. •• Benowitz N: Pharmacology of nicotine addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009, 49:57–71. This is a succinct description of the mechanisms underlying tobacco addiction and the principles surrounding its treatment.
27.
go back to reference Henningfield JE, Stapleton JM, Benowitz NL, et al.: Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993, 33:23–29.CrossRefPubMed Henningfield JE, Stapleton JM, Benowitz NL, et al.: Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993, 33:23–29.CrossRefPubMed
29.
go back to reference Haustein KO, Krause J, Haustein H, et al.: Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). Int J Clin Pharmacol Ther 2004, 42:83–92.PubMed Haustein KO, Krause J, Haustein H, et al.: Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). Int J Clin Pharmacol Ther 2004, 42:83–92.PubMed
30.
go back to reference Reichert V, Xue X, Bartscherer D, et al.: A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease. Chest 2009, 136:212–219.CrossRefPubMed Reichert V, Xue X, Bartscherer D, et al.: A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease. Chest 2009, 136:212–219.CrossRefPubMed
31.
go back to reference • Mohiuddin SM, et al.: Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007, 131:446–452. This article demonstrates the effectiveness and impact of a systematic approach to cessation in a cardiac setting. • Mohiuddin SM, et al.: Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007, 131:446–452. This article demonstrates the effectiveness and impact of a systematic approach to cessation in a cardiac setting.
32.
go back to reference Ockene IS, Miller NH: Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997, 96:3243–3247.PubMed Ockene IS, Miller NH: Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997, 96:3243–3247.PubMed
33.
go back to reference Wilson K, Gibson N, Willan A, Cook D: Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000, 160:939–944.CrossRefPubMed Wilson K, Gibson N, Willan A, Cook D: Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000, 160:939–944.CrossRefPubMed
34.
go back to reference Tonstad S, Johnston JA: Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil 2006, 13:507–514.CrossRefPubMed Tonstad S, Johnston JA: Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil 2006, 13:507–514.CrossRefPubMed
35.
go back to reference • Meyers DG, Neuberger JS, He J: Cardiovascular effect of bans on smoking in public places. A systematic review and meta-analysis. J Am Coll Cardiol 2009, 54:1249–1255. This article details the profound public health impact of smoking restriction. • Meyers DG, Neuberger JS, He J: Cardiovascular effect of bans on smoking in public places. A systematic review and meta-analysis. J Am Coll Cardiol 2009, 54:1249–1255. This article details the profound public health impact of smoking restriction.
36.
go back to reference Kahn R, Robertson JT, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008, 118:576–585.CrossRefPubMed Kahn R, Robertson JT, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008, 118:576–585.CrossRefPubMed
37.
go back to reference Forrester JS, Merz CN, Bush TL, et al.: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol 1996, 27:991–1006.CrossRefPubMed Forrester JS, Merz CN, Bush TL, et al.: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol 1996, 27:991–1006.CrossRefPubMed
38.
go back to reference Thorndike AN, Rigotti NA, Stafford RS, Singer DE: National patterns in the treatment of smokers by physicians. JAMA 1998, 279:604–608.CrossRefPubMed Thorndike AN, Rigotti NA, Stafford RS, Singer DE: National patterns in the treatment of smokers by physicians. JAMA 1998, 279:604–608.CrossRefPubMed
39.
go back to reference Pipe A: Tobacco and cardiovascular disease: achieving smoking cessation in cardiac patients. In Evidence Based Cardiology, 3rd Edition. Edited by Yusuf S. Oxford: Blackwell Publishing; 2010. Pipe A: Tobacco and cardiovascular disease: achieving smoking cessation in cardiac patients. In Evidence Based Cardiology, 3rd Edition. Edited by Yusuf S. Oxford: Blackwell Publishing; 2010.
40.
go back to reference Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005, 2:CD001292. Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005, 2:CD001292.
41.
go back to reference Reid R, Pipe A, Quinlan B: Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006, 22:775–780.PubMed Reid R, Pipe A, Quinlan B: Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006, 22:775–780.PubMed
42.
go back to reference Reid RD, Mullen K, Slovinec D’Angelo ME, et al.: Smoking cessation for hospitalized smokers: An evaluation of the "Ottawa Model". Nicotine Tob. Res. 2010, 12:11–18.CrossRefPubMed Reid RD, Mullen K, Slovinec D’Angelo ME, et al.: Smoking cessation for hospitalized smokers: An evaluation of the "Ottawa Model". Nicotine Tob. Res. 2010, 12:11–18.CrossRefPubMed
43.
go back to reference Rigotti NA, Munafo MR, Stead LF: Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst. Rev. 2007, 3:CD001837. Rigotti NA, Munafo MR, Stead LF: Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst. Rev. 2007, 3:CD001837.
44.
go back to reference Hubbard R, Lewis S, Smith C, et al.: Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005, 14:416–421.CrossRefPubMed Hubbard R, Lewis S, Smith C, et al.: Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005, 14:416–421.CrossRefPubMed
45.
go back to reference Joseph A, Fu S: Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003, 45:429–441.CrossRefPubMed Joseph A, Fu S: Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003, 45:429–441.CrossRefPubMed
46.
go back to reference Meine T, Patel M, Washam J, et al.: Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005, 95:976–978.CrossRefPubMed Meine T, Patel M, Washam J, et al.: Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005, 95:976–978.CrossRefPubMed
47.
go back to reference Stead LF, Perera R, Bullen C, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 1:CD000146. Stead LF, Perera R, Bullen C, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 1:CD000146.
48.
go back to reference Tonstad S, et al.: Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003, 24:946–955.CrossRefPubMed Tonstad S, et al.: Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003, 24:946–955.CrossRefPubMed
49.
go back to reference Rigotti NA, Pipe AL, Benowitz NL, et al.: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A randomized trial. Circulation 2010, 121:221–229.CrossRefPubMed Rigotti NA, Pipe AL, Benowitz NL, et al.: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A randomized trial. Circulation 2010, 121:221–229.CrossRefPubMed
50.
go back to reference Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007, 1:CD006103. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007, 1:CD006103.
Metadata
Title
The Role of Smoking Cessation in the Prevention of Coronary Artery Disease
Authors
Andrew L. Pipe
Sophia Papadakis
Robert D. Reid
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 2/2010
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-010-0105-8

Other articles of this Issue 2/2010

Current Atherosclerosis Reports 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.